{"id":501105,"date":"2020-08-07T20:14:01","date_gmt":"2020-08-07T20:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501105"},"modified":"2020-08-07T20:14:01","modified_gmt":"2020-08-07T20:14:01","slug":"chronic-inducible-urticaria-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inducible-urticaria-epidemiology-forecast-till-2030_501105.html","title":{"rendered":"Chronic Inducible Urticaria Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Inducible Urticaria Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Chronic Inducible Urticaria Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Chronic Inducible Urticaria Epidemiology Forecast to 2030\u2019 report delivers an in-depth understanding of the disease, historical and forecasted chronic inducible urticaria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">Chronic Inducible Urticaria is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema, or both, as a response to specific triggers.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">Key Highlights from the report:-<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The total <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-inducible-urticaria-epidemiology-forecast\">Chronic Inducible Urticaria prevalent population<\/a><\/strong> in 7MM was 652,542 in 2017.<\/li>\n<li>The total <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-inducible-urticaria-epidemiology-forecast\">prevalent cases for Chronic Inducible Urticaria<\/a><\/strong> were highest in the United States, followed by Germany and France among 7MM countries.&nbsp;<\/li>\n<li>About 50% of cases of Chronic Inducible Urticaria are symptomatic dermographism, and 20% each are cold urticaria and cholinergic urticaria; the other 10% are the different forms of Chronic Inducible Urticaria.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The chronic inducible urticaria (CIndU) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The CIndU report and model provide an overview of the global trends of CIndU in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).<\/li>\n<li>The report provides insight into the historical and forecasted patient pool of CIndU in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM concerning the patient population.<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of chronic inducible urticaria.<\/li>\n<li>The report provides the segmentation of the Chronic Inducible Urticaria epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inducible-urticaria-epidemiology-forecast\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inducible-urticaria-epidemiology-forecast\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1 Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2 Executive Summary of Chronic Inducible Urticaria<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3 SWOT Analysis for Chronic Inducible Urticaria<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4 Chronic Inducible Urticaria Epidemiology Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030<\/p>\n<p style=\"text-align: justify;\"><span>5 Chronic Inducible Urticaria Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030<\/p>\n<p style=\"text-align: justify;\"><span>6 Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.1 Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.2 Types<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.3 Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.4 Clinical features<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.5 Diagnosis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.6 Clinical manifestation<\/p>\n<p style=\"text-align: justify;\"><span>7 Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1 Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2 Total Prevalent Population of CIndU in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3 Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\"><span>8 Country-wise Epidemiology of Chronic Inducible Urticaria<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1 The United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.1 Diagnosed Prevalent cases of CU in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.2 Diagnosed Prevalent cases of CIndU in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2 EU5<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.1 Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.2 France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.3 Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.4 Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.5 The United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.3 Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.1 Diagnosed Prevalent cases of CU in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.2 Diagnosed Prevalent cases of CIndU in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan<\/p>\n<p style=\"text-align: justify;\"><span>9 Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.1 Guidelines<\/p>\n<p style=\"text-align: justify;\"><span>10 Case Study<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.1 Severe cold urticaria including anaphylaxis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.2 Severe symptomatic dermographism (urticaria factitia)<\/p>\n<p style=\"text-align: justify;\"><span>11 Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12 Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13 Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1 Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>14 DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15 Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16 About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-inducible-urticaria-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-inducible-urticaria-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Chronic Inducible Urticaria Epidemiology Forecast to 2030\u2019 report delivers an in-depth understanding of the disease, historical and forecasted chronic inducible urticaria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inducible-urticaria-epidemiology-forecast-till-2030_501105.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501105","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501105"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501105\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501105"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501105"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}